New research led by the University of Liverpool in collaboration with the University of New South Wales (Sydney, Australia) ...

Mumbai: Astellas Pharma India Pvt Ltd. today announced that PADCEV TM (enfortumab vedotin) is now available for prescription in India as monotherapy for the treatment of adult patients with ...

Crystallography-informed AI achieves high performance in predicting novel crystal structures by Research Organization of Information and Systems ...

Enfortumab vedotin plus pembrolizumab is more effective than chemotherapy as first-line treatment for metastatic urothelial cancer, data suggest.

Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: hint of major added benefit. Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new ...

Mar 05, 2025 Liquid crystal structures key to organic solar cell performance Researchers improved organic solar cell fabrication by controlling molecular assembly, enhancing efficiency and stability, ...

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.

This release contains forward-looking information about Pfizer Oncology and PADCEV®(enfortumab vedotin-ejfv) in combination with pembrolizumab in patients with previously untreated locally ...

Scientists use math to predict crystal structure in hours instead of months Date: November 14, 2024 Source: New York University Summary: Researchers have devised a mathematical approach to predict ...

"Most liquid-crystal-based devices are made from single-layer structures, but this limits light field modulation to a confined area," said research team leader Fan Fan from Hunan University in China.

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical trial, and its efficacy was not inferior in patients with diabetes and/or neuropathy.

Enfortumab vedotin (EV) is the first drug in this new class to be approved by the EMA at for the treatment of patients and patients with metastatic urothelial carcinoma.